Company ProfilePremium

Bubs Australia Limited

Company Profile Analysis

Ticker: BUB.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bubs Australia Limited - Company showcase

Year Founded & Workforce

2006

80 Employees

Bubs Australia Limited logo

Bubs Australia Limited Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Bubs Australia Limited Overview

Bubs Australia is a small-cap, Melbourne-based specialist in premium infant nutrition, built around goat-milk infant formula and complemented by A2 beta-casein bovine, organic grass-fed and a value-tier "Essential" range, plus CapriLac adult goat milk powder sold mainly in China. It owns its Victorian canning and blending operation (Deloraine Dairy) and sources Australian goat milk under a "farm-to-formula" model. Having entered the US during the 2022 formula shortage under FDA enforcement discretion, Bubs has repositioned from a China-dependent exporter into a US-led business: the US delivered A$65.8m, or roughly 59% of FY26 revenue of A$111.9m. On 7 September 2026 it secured permanent FDA authorisation for three formulas, making it, by its own account, the only Australian infant formula brand with permanent US access. The company is the #1 goat formula brand in Australia and on Amazon US, but remains marginally profitable, working-capital intensive and exposed to regulatory, tariff and freight shocks.


Company's own description. In its FY25 Annual Report, Bubs describes its principal activities as offering goat milk infant formula products, adult goat milk powder products, organic baby food and fresh dairy products, with the Group's principal activity being the manufacture and sale of infant formula, adult goat milk powder, fresh dairy products and organic baby food. Its current corporate boilerplate (FY26 announcements) positions it as a leading infant nutrition company offering organic and specialty formulas, including goat milk and grass-fed options, with a presence in Australia, the US and international markets including China. Its stated purpose (FY26 Results Presentation) is to provide clean nutrition products that give parents peace of mind and support lifelong wellbeing for babies; its mission (Strategy Update, Mar 2026) is to make naturally gentle, clean nutrition the first choice for modern parents—recognisably Australian and trusted globally.

Independent characterisation. Bubs is a branded, product-led consumer staples business operating a partially vertically integrated model. It controls the final manufacturing stages (blending and canning at its Victorian facility, Deloraine Dairy, acquired 2019), procures goat milk from Australian farms (herd expanded >70% in FY26), and uses third-party partners for base powders, non-dairy ingredients, logistics and in-market distribution. Revenue is almost entirely product sales recognised at the point of transfer, net of trade spend, rebates and marketing contributions; there is no subscription or licensing revenue of note, and only immaterial services (contract canning, A$0.6m in FY24, nil in FY25).

Revenue model mix (FY25 Annual Report, Note B2).

FY26 product-level disaggregation was not disclosed in the results materials reviewed.

Value chain position. Per the Strategy Update (Mar 2026), the chain runs from milk collection on Australian farms, through spray drying (partner-supplied base powder), blending of functional ingredients and canning with tin-level traceability (Bubs-controlled), to integrated global logistics and omnichannel consumer engagement. Management is explicitly migrating from a single-source Australian supply chain to a multi-partner global network with market-proximate manufacturing, described as asset-light (Strategy Update, Mar 2026).

Customer types and channels.

USA: National and regional retailers (Target, Walmart, Kroger, H-E-B, Meijer, Sprouts, Giant Eagle, Sam's Club) and e-commerce (Amazon, where Bubs is the #1 goat infant formula); 10,000+ doors across all 50 states by July 2026 (FY26 Presentation).

China: Cross-border e-commerce (Tmall Global, JD.com, Douyin) and online-to-offline (O2O) mother-and-baby stores (1,800+ stores in FY26; entry to KidsWant, China's largest mother & baby chain, in late June 2026).

Australia: Woolworths, Coles, Metcash, pharmacy (e.g., My Chemist/Chemist Warehouse group), specialty, Amazon Australia.

Rest of World: Distributor-led markets — Japan, Vietnam, Malaysia, Saudi Arabia, Singapore, Cambodia; Canada entry flagged in FY26.

Concentration: Two customers each exceeded 10% of FY25 revenue, totalling A$29.8m (one customer, A$20.0m, in FY24) (FY25 Annual Report).

End-markets served. Infant milk formula (stage 1–2), toddler/growing-up milk, adult goat milk powder (China-centric), and historically organic baby food (Australian food portfolio discontinued in 1H FY26 per company commentary reported by Stockwirex).

Strategy

Strategic evolution. In 2023 the reconstituted board set a five-pillar plan: (1) USA as the growth engine; (2) China reset; (3) portfolio optimisation; (4) "sweat the assets" (Deloraine utilisation); and (5) working capital discipline (FY25 AR). Under Joe Coote, this was superseded by the 2030 strategy unveiled at the Strategy Update Day on 26 March 2026.

2030 strategy architecture (Strategy Update, Mar 2026; FY26 Presentation).

Purpose: Clean nutrition delivering peace of mind for parents and lifelong wellbeing for babies.

Values: Transparency, Courage, Collaboration, Inspiration.

Pillar 1 – Activate Brand and Consumer: Evolve the brand to a "naturally gentle, backed by science, of Australia" positioning; build intimacy with "Zillennial" urban, high-income, digitally engaged parents aged 25–40 (repeat purchase rates of 28–54%); data-driven digital marketing using marketing-mix modelling, retail media (Amazon DSP, Walmart Connect, Target Roundel) and social (Meta, TikTok, Reddit).

Pillar 2 – Build a Winning Portfolio: Profitable growth across Strategic markets (USA, China, Australia), Growth markets (Canada, Mexico, Vietnam) and Partner markets (Japan, Cambodia, Middle East); goat and bovine renovations; optionality for adjacencies (supplements, RTD, snacks, personal care), private label, manufacturing diversification and partnerships. Product ladder: infant formula (core entry) → infant supplements → toddler nutrition → snacks → adult nutrition (adjacent brand).

Pillar 3 – Connect Farm to Formula: Operational excellence; capacity expansion based on optimal scale and partner model; technology for traceability; shift from single-source to global multi-partner network with market-proximate manufacturing.

Enablers: Performance culture, Transformation Office (PMO) with stage-gated capital allocation and defined payback thresholds, innovation pipeline, strategic partners, digital and AI adoption.

Market ambitions. USA: top-3 premium natural IMF and top-2 goat IMF brand; expand in under-penetrated regions (e.g., Northeast), club, drug and specialty; relaunch website with e-commerce, CRM and education platform; enter super-premium. China: expand general trade including China-label (SAMR) products via mother-and-baby chains (e.g., KidsWant), invest in lower-tier cities, extend into supplements. Australia: drive trial in goat and organic, increase premium mix, improve in-store and e-commerce execution.

Initiatives delivered or in progress (last 24 months).

Financial targets and guidance history.

Medium-term framework (Strategy Update): Double-digit revenue growth with operating leverage; revenue and margin growth to outpace working capital growth; positive operating cash flow; capital-light balance sheet through the cycle.

Products & Services

All products sit within the single reported segment. Pricing is not publicly disclosed in filings; Bubs positions as premium in all markets, with the Essential range as its value-tier entry.

Historic US portfolio: All six Bubs infant formula products entered the US in June 2022 under enforcement discretion (Q4 FY22 4C). The permanent authorisation covers three SKU families (Goat, 365 Day Grass Fed, Essential); the NIFS lodged June 2025 covered these three.

Product Portfolio

Product / brandDescription & key attributesTarget customerLaunch / latestMarketsNotes

Bubs Goat Milk Infant Formula ("Easy-Digest")

Goat-milk based infant formula (stages 1–3 historically); positioned on gentle digestion; Clean Label Project Purity Award five years running; certified pesticide-free

Parents seeking gentle-digestion, clean-label formula; combo-feeding and early switchers

Goat range launched c.2013; packaging refresh FY25

Australia, US, China (CBEC/O2O), ROW

Flagship; #1 goat formula in Australia (53.5% sub-category share FY25), #1 goat IMF on Amazon US; covered by permanent FDA authorisation (Sep 2026)

Bubs 365 Day Grass Fed (US name) / Bubs Organic Grass-fed (AU)

Bovine formula from grass-fed / certified organic milk

Organic/natural-seeking parents

Organic formula launched c.2017 per timeline

US, Australia, ROW

Covered by permanent FDA authorisation

Bubs Essential(s)

Competitively priced bovine formula extending into mainstream segment

Value-conscious parents

Launched FY25 (Australia, ranged at Woolworths)

Australia, US

Covered by permanent FDA authorisation

Bubs Supreme A2 Beta-Casein Protein

Bovine formula using A2 beta-casein protein milk

Premium A2-seeking parents (China and Australia)

Launched c.FY22

China (CBEC), Australia, ROW

China inventory overhang cleared in FY24; key FY25 China growth driver

Bubs toddler / growing-up milk

Toddler milk drinks (goat and bovine)

Parents of 1–3 year olds

Ongoing; China "Kids" growing-up extension launched FY26

Australia, China, ROW

Lifecycle extension per 2030 strategy

CapriLac adult goat milk powder

Adult goat milk powder; China label version launched FY26; offline expansion into ~100 premium retail outlets

Adults/families, primarily in China

Acquired with NuLac Foods 2017

China (Tmall Global), Australia

Won Tmall Global category award (FY26); adult revenue A$12.4m in FY25

Bubs Organic baby food (pouches, cereals)

Organic baby food range

Infants on solids

Long-standing; Australian food portfolio discontinued 1H FY26

Australia (historically), ROW

"Nutritional products" revenue A$1.1m FY25

New formats (pipeline)

Powder sachets and ready-to-drink (RTD) formats; infant supplements

Convenience/premium buyers

Flagged FY26 Strategy Update

China (first), US adjacencies

Part of "Build a Winning Portfolio" pillar

Club pack

Bulk format launched at Sam's Club

Bulk-buying US consumers

FY26

US

Retail execution initiative

Contract manufacturing / private label (prospective)

FDA variant application lodged 9 Sep 2026 to pursue contract manufacturing

US retailers/brands

Prospective

US

Subject to further regulatory, technical and commercial milestones

Fresh dairy

Fresh goat dairy products (legacy NuLac business)

Australian consumers

Legacy

Australia

Referenced in FY25 principal activities; revenue immaterial/not separately disclosed

Financial Narrative

Income statement: notes and sources

Sources: FY25 Annual Report five-year summary and statements (FY22–FY25); FY26 Results Presentation; FY23/FY24 results releases; FY22 annual results. FY24 and FY25 EPS in cents derived from NPAT and weighted shares (832.3m and 893.0m); FY26 EPS derived using ~893m shares. FY22/FY23 EPS as reported in FY25 AR (rounded to whole cents).

Margins and growth

Derived from 6.1. Underlying margins use "as reported at the time" for FY22–FY24, restated for FY25. Opex ratios per company (FY25 AR; FY26 Presentation; FY25 shown as 45% on FY26 basis, 44% on FY25 AR basis).

Revenue CAGR (derived): FY22–FY26 four-year CAGR ≈ 5.8% (distorted by the FY22 China/daigou and Operation Fly Formula spike); FY23–FY26 three-year CAGR ≈ 23.0%. Management cites a 3-year CAGR of 26% using FY26 guidance of A$120–125m that was subsequently missed (Strategy Update).

FY26 earnings bridge

Total tariff-related costs were A$2.6m (H1 A$0.3m, H2 A$2.3m), of which A$1.0m of non-AU tariffs is excluded from underlying EBITDA. Item-by-item arithmetic as presented sums to ~A$5.5m versus the stated A$5.3m; the difference is presumably rounding or presentation and is flagged rather than resolved.

Balance sheet: notes and sources

Sources: FY25 AR statements; FY26 Results Presentation; Q4 FY22 4C (FY22 cash, pre-A$63m raise); FY24 opening balances (FY23 cash and equity). FY23 borrowings derived from FY24 cash flow (closing A$5.28m less A$4.8m drawn plus A$1.8m repaid). FY26 net current assets derived (current assets A$60.5m less current liabilities A$27.7m). FY26 debt: A$10.0m drawn under bank facilities with A$10.0m undrawn; NAB facility extended to 31 Aug 2027. Goodwill stands at only A$0.57m after cumulative impairments of A$90.0m against A$90.6m gross goodwill.

Cash flow

FY26 capex shown as total investing cash flow. FY22 raise of A$63m was announced and largely settled around July 2022 (straddling FY22/FY23). FY24 raise of A$17.4m (net A$15.7m after costs).

Ratios (derived)

ROIC and cash conversion cycle not computed due to insufficient disclosed detail.

Commentary on trends, inflections and drivers

Three regimes. The five-year record divides into (i) a volatile China-led boom and bust (FY21–FY23), (ii) a turnaround under new governance (FY24–FY25), and (iii) a growth-investment year disrupted by external shocks (FY26). FY22 revenue of A$89.3m was flattered by a five-fold increase in corporate daigou revenue in China and two Operation Fly Formula flights in June 2022. The collapse in FY23 (revenue −32.7%, China −73%) reflected inventory overhang with the former exclusive China distributor (Alice/Willis), resulting in A$36.2m of non-cash impairments against Deloraine and NuLac assets, negative gross profit due to inventory provisions, and a statutory loss of A$108.4m.

Turnaround. FY24 restored a 48.6% gross margin (partly aided by A$20.6m of inventory provision reversals) and grew revenue 33% as the US scaled. FY25 was the inflection: opex-to-revenue fell from 73% to 44%, operating cash flow turned positive at A$6.1m (three consecutive positive quarters), and Bubs recorded its maiden statutory profit of A$5.5m, aided by A$3.6m of legal credit recoveries and a A$1.3m insurance receipt that were excluded from underlying EBITDA of A$0.6m.

FY26 disruption. Revenue grew 9.2% to A$111.9m, short of the A$120–125m guidance reiterated in February and March 2026, after H2 disruption from a "regulatory reset" (new labelling/registration requirements that paused trading in Vietnam and Singapore and slowed China customs clearance), US tariffs, and airfreight to restore US stock. Reported gross margin compressed eight points to 39.8%, while underlying gross margin held at 46.8%. Underlying EBITDA rose to A$5.3m, demonstrating operating leverage when one-offs are excluded, but reported EBITDA was −A$1.8m and NPAT −A$4.6m. The A$16.2m inventory rebuild (A$20.1m → A$36.3m) drove a A$15.1m operating cash outflow, cutting cash to A$9.4m and requiring A$10.0m of bank drawings. Management states the restocking is complete and NWC/sales has normalised at 31.7%.

Quality of earnings. Investors should weight underlying measures cautiously: in each of FY25 and FY26, items excluded from underlying EBITDA were material relative to the result (FY25: A$4.9m of credits removed; FY26: A$7.1m of costs added back). The FY25 accounts were prepared on a going-concern basis with an explicitly disclosed material uncertainty tied to FDA approval; that key assumption has now been satisfied (Sep 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Market revenue (AUD Mn)

Market revenue (AUD Mn)FY23FY24FY25FY26

USA

23.935.053.165.8

China

13.617.321.121.4

Australia

17.421.619.818.3

Rest of World

5.35.98.56.4

Total

60.179.7102.5111.9

Market YoY growth (%)

Market YoY growth (%)FY24FY25FY26

USA

465224

China

27221

Australia

24-8-7

Rest of World

1144-25

Group

33299

Share of revenue (%)

Share of revenue (%)FY23FY24FY25FY26

USA

40445259

China

23222119

Australia

29271916

Rest of World

9786

Income Statement and Per-Share Data

MetricFY22FY23FY24FY25FY26

Revenue (AUD Mn)

89.360.179.7102.5111.9

Gross profit (AUD Mn)

28.9-9.438.749.144.5

Underlying gross profit (AUD Mn)

———49.752.3

Operating expenses (AUD Mn)

———46.548.8

EBIT / operating profit (AUD Mn)

-10.4-107.6-21.24.5-3.4

Reported EBITDA (AUD Mn)

-7.8-105.2-19.75.2-1.8

Underlying EBITDA as reported at the time (AUD Mn)

4.8-34.4-19.70.65.3

Underlying EBITDA latest restated basis (AUD Mn)

—-69.1-20.31.25.3

Pre-tax income (AUD Mn)

-11.3-107.5-20.55.5—

Net income after tax (AUD Mn)

-11.4-108.4-21.05.5-4.6

Basic EPS (A$ cents)

-2-15-2.50.6-0.5

Diluted EPS (A$ cents)

-2-15-2.50.6-0.5

Dividends per share (A$ cents)

00000

Margin Analysis (%)

Metric (%)FY22FY23FY24FY25FY26

Revenue growth (%)

127.2-32.732.628.79.2

Gross margin (%)

32.4-15.648.647.839.8

Underlying gross margin (%)

———48.546.8

Operating (EBIT) margin (%)

-11.7-178.9-26.54.4-3.0

Reported EBITDA margin (%)

-8.7-175.1-24.75.1-1.6

Underlying EBITDA margin (%)

5.4-57.2-25.51.24.7

Net margin (%)

-12.8-180.4-26.35.4-4.1

Opex to revenue (%)

——734544

Bridge Item Details

Bridge itemFY26

Reported EBITDA

-1.8

Add: USA airfreight (H1 1.9, H2 1.1)

3.0

Add: Regulatory reset (all H2)

3.9

Add: USA non-AU tariff

1.0

Less: Alice & Willis settlement credit

-0.8

Add: Restructure costs

0.2

Underlying EBITDA (company stated)

5.3

Balance Sheet and Margin Analysis (%)

MetricFY22FY23FY24FY25FY26

Total assets (AUD Mn)

——66.857.272.2

Cash and equivalents (AUD Mn)

16.326.117.517.49.4

Inventories (AUD Mn)

——28.220.136.3

Short-term borrowings (AUD Mn)

—2.35.30.010.0

Long-term borrowings (AUD Mn)

—0.00.00.00.0

Lease liabilities (AUD Mn)

——1.71.0—

Net debt excl. leases (AUD Mn)

—-23.8-12.2-17.40.6

Total equity (AUD Mn)

—41.736.942.539.0

Goodwill and intangibles (AUD Mn)

—1.21.21.2—

Net current assets (AUD Mn)

——31.137.032.8

Net working capital, company definition (AUD Mn)

——24.323.235.5

NWC to sales (%)

——30.522.631.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY22FY23FY24FY25FY26

Operating cash flow (AUD Mn)

—-46.5-26.36.1-15.1

Capex incl. intangibles (AUD Mn)

——-0.2-0.1-1.2

Free cash flow (AUD Mn)

——-26.56.0-16.3

Financing cash flow (AUD Mn)

——18.0-6.08.3

Equity raised gross (AUD Mn)

63.00.017.40.00.0

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY24FY25FY26

ROE (%, on average equity)

-53.413.9-11.3

ROA (%, on average assets)

—8.9-7.1

Current ratio (x)

2.093.652.18

Debt to equity (x, excl. leases)

0.140.000.26

Net debt to underlying EBITDA (x)

——0.11

Interest coverage, EBIT/interest (x)

—9.2—

Asset turnover (x)

—1.651.73

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY22FY23FY24FY25FY26

USA

8.023.935.053.165.8

China

49.413.617.321.121.4

Australia

14.517.421.619.818.3

Rest of World

17.45.35.98.56.4

Total

89.360.179.7102.5111.9

Region revenue (AUD Mn) (Half-Yearly)

Region revenue (AUD Mn)1H FY241H FY251H FY26

USA

18.223.234.2

China

7.110.27.5

Australia

11.710.59.6

Group

39.448.555.5

Share price (AUD)

Share price (AUD)FY21FY22FY23FY24FY25

Share price at 30 June (AUD)

0.4350.5950.1800.1300.170

Recent Price Points Details

Recent price points (AUD)DatePrice

AGM

20 Nov 2025

0.150

Q2 update

30 Jan 2026

0.130

1H results

27 Feb 2026

0.120

Strategy Day

26 Mar 2026

0.105

Trading downgrade

29 May 2026

0.094

Pre-FDA halt

4 Sep 2026

0.100

FDA approval close

7 Sep 2026

0.135 (intraday 0.145)

52-week high (approx.)

—

~0.165

Valuation Multiples

MultipleBubs (FY26)Peer reference

Market capitalisation

≈A$116m

—

Enterprise value (mkt cap + A$10.0m debt − A$9.4m cash; excl. leases)

≈A$117m

—

P/E

n.m. (loss)

—

EV/Sales

≈1.0x

—

EV/Underlying EBITDA (A$5.3m)

≈22x

—

P/B (equity A$39.0m)

≈3.0x

FNArena showed P/B 3.78x (Mar 2026 data)

Analyst Ratings & Targets

BrokerDateView / targetNotes

Bell Potter

8 Sep 2026

Price target raised from A$0.135 to A$0.19

Post-FDA

Shaw and Partners

Mar 2026

—

Praised 1H EBITDA beat

TipRanks aggregate

Pre-Sep 2026

Three buy ratings; average target ~A$0.13

Pre-FDA

Debt (AUD Mn)

Debt (AUD Mn)FY24FY25FY26

Drawn bank borrowings (AUD Mn)

5.30.010.0

Undrawn facilities (AUD Mn)

4.710.010.0

Analyst Conclusions

Management guidance (27 Aug 2026). Qualitative only for 1H FY27: improved momentum as the business adapts to the new regulatory and US tariff environment; positive revenue growth with mixed regions (USA continued strong growth; China growth from distribution and marketing; Australia continued marketing investment; ROW mixed but product flows improving); gross margin expected to rebound; working capital positioned for growth; continued brand investment; FDA process now finalised.

Bell Potter's 19c target implies ~45% upside from 13c. Management's framework targets double-digit revenue growth with operating leverage.

Bull case

  1. Regulatory moat now permanent: With FDA authorisation secured, the US (59% of revenue, +24% in FY26 even while supply-constrained) can compound as 10,000+ doors mature and retailer conversations broaden to private label.

  2. Margin rebound is mechanical: Underlying gross margin was 46.8% versus 39.8% reported; if airfreight (A$3.0m) and regulatory reset (A$3.9m) costs do not recur, reported EBITDA could move toward the A$5–10m range on modest growth.

  3. Inventory investment done: The A$16.2m restock is complete; normalised NWC/sales of 31.7% means future growth should be less cash-hungry, supporting positive operating cash flow.

Bear case

  1. Recurring "one-offs": Freight, tariffs and regulatory costs recurred across quarters; Bubs' Australia-to-US supply chain is structurally exposed, and underlying EBITDA may overstate sustainable earnings.

  2. Balance sheet limits: A$9.4m cash and A$10m drawn debt constrain marketing versus multinationals; any stumble could force dilutive equity (raises of A$63m in 2022 and A$17.4m in 2023).

  3. Execution and credibility: FY26 guidance was cut sharply three months after reaffirmation; leadership churn is high; Australia continues to lose ground and China growth has stalled.

Key catalysts and monitorables (next 12 months)

  • 1H FY27 results (Feb 2027) and quarterly 4Cs (Oct 2026, Jan 2027, Apr 2027, Jul 2027): gross margin recovery toward 45%+ and positive operating cash flow.

  • US scan data: velocity per store across 10,000+ doors; goat share versus Kendamil/Kabrita.

  • Outcome of the FDA variant application and any announced private-label/contract-manufacturing agreement.

  • US tariff policy on Australian dairy imports; freight normalisation.

  • Vietnam relaunch (1H FY27) and Singapore resumption; China customs normalisation; KidsWant sell-through.

  • Australian share recovery after H2 FY26 marketing step-up.

  • AGM (expected Nov 2026): board renewal, remuneration votes, potential FY27 numeric guidance.

  • NAB facility renewal ahead of 31 Aug 2027; capital management decisions.

Concluding analyst verdict

Bubs Australia has emerged from a near-death sequence — a China channel collapse, A$108m statutory loss and a bitter governance war in FY23 — into a credible, US-led specialist infant nutrition brand. The September 2026 permanent FDA authorisation is the single most important event in the company's listed history: it converts a temporary, shortage-era foothold into a durable licence to operate in the world's most profitable premium formula market, removes the going-concern uncertainty disclosed in the FY25 accounts, and opens a private-label option that could use the Victorian plant's idle third shift.

Yet the FY26 result shows how far Bubs remains from being a robust earnings compounder. A business generating A$112m of revenue absorbed nearly A$8m of freight, regulatory and tariff costs, swung to a A$4.6m net loss, and burned A$15m of operating cash to rebuild inventory, leaving only A$9.4m of cash. Guidance credibility was damaged by a mid-year downgrade, the home market is shrinking, China is flat, and leadership has turned over repeatedly. Underlying EBITDA of A$5.3m (4.7% margin) compares with a2 Milk's ~15% margin at roughly eighteen times the scale, underscoring the operating-leverage gap Bubs must close.

At roughly A$116m market capitalisation (≈1.0x EV/sales, ≈22x EV/underlying EBITDA), the market is pricing a partial — not full — normalisation. The investment case now hinges on execution rather than regulation: demonstrating that reported gross margins return to the mid-40s, that the expanded US footprint produces rising velocity rather than one-off pipeline fills, and that growth can be funded internally. If 1H FY27 delivers positive operating cash flow and reported EBITDA consistent with underlying trends, a re-rating toward broker targets is plausible. Absent that, the stock remains a high-risk, catalyst-driven small cap. Verdict: speculative, improving fundamentals with materially de-risked regulatory position; balance-sheet and execution risk keep it a watch-and-verify position pending 1H FY27 evidence.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundEducation

Joe Coote

CEO (from 28 Jul 2025); Managing Director (board from Sep 2025)

Former CEO of Darigold (fourth-largest US dairy co-operative); ~12 years at Fonterra in senior roles including President across US, Asia and ANZ; 20+ years FMCG/dairy/infant nutrition; returned to Australia after ~15 years abroad

—

Chris Rowe

Chief Financial Officer

In role by Aug 2026 (co-hosted FY26 results); appointment date not disclosed in sources reviewed

—

Naomi Verloop

Former CFO (appointed 10 Feb 2025)

Presented at Mar 2026 Strategy Day; departure date not disclosed in sources reviewed

—

Richard Paine

Chief Operating Officer

Long-serving; interim CEO May–Aug 2023

—

Jasmin Manner

President – US

Leads largest market

—

Jackie Lin

General Manager – China

Leads China business

—

Chris Lotsaris

General Manager – Australia and ROW

——

Annie Chen

Chief Marketing Officer

Leads global brand refresh

—

Kathryn O'Hehir

General Manager – Corporate Services

Leads Transformation Office

—

Peter Cope

General Counsel (from 18 Jan 2022) and Company Secretary (from 1 Jan 2025)

Ex-Hall & Wilcox, AusNet Services, Murray Goulburn, Melbourne Airport; Chartered Accountant (ex-Deloitte)

BSc, BCom, LLB, LLM (University of Melbourne)

“—” = not publicly disclosed.

Board of Directors

DirectorRoleAppointedIndependenceBackground

Paul Jensen

Independent Chair (from Sep 2025); previously Chair of Audit & Risk Committee

20 Mar 2023

Independent

20+ years as professional director; prior NED roles include Hunter Hall Global Value, Sandon Capital, RHG, WAM Capital, Foodco Group, Forty Winks; Director of Australian Made Campaign, Alterra, GNS Wholesale; executive career incl. Lloyds Bank; BCom (Victoria University of Wellington); FAICD

Joe Coote

Managing Director & CEO

Board from Sep 2025

Executive

See above

Steve Lin

Non-Executive Director

18 Apr 2019

Non-independent (represents C2 Capital, largest holder)

Managing Partner, C2 Capital Partners; boards of Stella & Chewy's, Petcurean, KDC/ONE; ex-Morgan Stanley, Goldman Sachs; economics degree, Harvard College; based in US

Lori Tauber Marcus

Independent Non-Executive Director

21 May 2026

Independent

US-based; 24 years at PepsiCo; former EVP and Chief Global Brand & Product Officer at Keurig; boards include Fresh Del Monte Produce, Primo Water, Phunware

Directors' Remuneration

KMP (AUD)Salary & feesSTISuperShare-basedOther (leave/LSL)Total FY25Total FY24

Reg Weine (CEO/MD to 28 Jul 2025)

738,629676,71029,932343,61967,5601,856,450990,640

Richard Paine (COO)

409,360213,03729,93220,35134,813707,493548,708

Naomi Verloop (CFO from Feb 2025)

136,25876,23312,47218,98612,413256,3620

Aaliyah Nyathi (Interim CFO Oct 2024–Feb 2025)

98,20009,66906,354114,2230

Robin Johnston (CFO to Sep 2024)

66,27706,86706,87280,016355,046

Katrina Rathie (Chair)

206,000023,69000229,690232,696

Paul Jensen (NED)

149,3000000149,300141,525

Steve Lin (NED)

0000000

Major Shareholders

HolderShares%Source / date

C2 Capital Partners (Alibaba-anchored PE; represented by Steve Lin)

76,288,5108.54

FY25 AR (30 Jun 2025)

Paul Jensen (Chair, via Taranaki Holdings)

≈3,630,890 (derived)

≈0.4

500,000 at 30 Jun 2025 + 630,890 (Sep 2025) + 1,000,000 (Mar 2026) + 1,500,000 (31 Aug–1 Sep 2026, ~A$130,500 at 8.55–8.7c)

Richard Paine (COO)

561,967

<0.1

FY25 AR

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning vs Bubs

The a2 Milk Company (ASX: A2M)

A2 bovine IMF (Australia, China, US)

Far larger (NZ$1.97bn FY26 revenue); vertically integrating (a2 Pōkeno); direct rival to Bubs Supreme

Abbott (Similac)

US mass and premium IMF

US category leader; 2022 Sturgis recall triggered the shortage that opened the US to Bubs

Reckitt / Mead Johnson (Enfamil)

US mass and premium

Major US incumbent with WIC exposure

Nestlé (Gerber, NAN, illuma)

Global, US, China, Australia

Global scale and science resources

Danone (Aptamil, Karicare incl. goat variant)

Australia, China, global

Leading Australian/China premium player; Karicare Goat competes directly

Perrigo (store brands)

US private label

Relevant if Bubs pursues private label

Kendal Nutricare (Kendamil, including goat)

US premium/natural, goat

Fast-growing UK whole-milk/goat brand in US

Ausnutria (Kabrita goat)

Goat IMF in US, China

Leading global goat specialist

Dairy Goat Co-operative NZ / Nuchev (Oli6)

Goat IMF Australia/China

Goat category rivals

ByHeart, Bobbie

US premium natural (FDA-registered US makers)

Venture-backed US challengers in premium natural

Bellamy's Organic (Mengniu)

Organic IMF Australia/China

Competes with Bubs Organic

Peer Comparison FY2026

MetricBubs Australia (FY26)a2 Milk Company (FY26)

Revenue

A$111.9m

NZ$1,974.9m

Revenue growth

9.2%12.4%

Gross margin

39.8% (underlying 46.8%)

47.7%

EBITDA margin

-1.6% (underlying 4.7%)

14.4% (underlying 15.6%)

US growth

24%

28.6% (USA segment)

Recent Developments

--

Company Snapshot

$72.2M

Revenue

80

Employees

2006

Founded

Dandenong South, Australia

Headquarters

SWOT Analysis

Strengths

  • Permanent US regulatory access: FDA authorisation on 7 Sep 2026 for Goat, 365 Day Grass Fed and Essential, removing the binary risk flagged in the FY25 going-concern note.
  • US growth engine: US revenue rose from A$8.0m (FY22, derived) to A$65.8m (FY26), a 59% share of group revenue.
  • Goat category leadership: 53.5% of Australian goat IMF (FY25), 20% of US goat IMF (FY26), #1 goat on Amazon US.
  • Distribution breadth: 10,000+ US doors across all 50 states, plus national availability via Amazon, Target and Walmart (FY26 Presentation).
  • Healthy underlying gross margin: 46.8% underlying (FY26) and 47.8% reported (FY25), comparable to a2 Milk's 47.7%.
  • Owned manufacturing with spare capacity: Deloraine runs two shifts with a third available; capex needs low (FY25 capex A$0.1m).
  • Clinical evidence base: 478-infant US study, described as the largest single US IMF clinical trial.

Weaknesses

  • Earnings fragility: Reported EBITDA swung from +A$5.2m (FY25) to −A$1.8m (FY26) on A$7.9m of freight, regulatory and tariff costs.
  • Thin liquidity: Cash fell from A$17.4m to A$9.4m in FY26 with A$10.0m drawn debt (net debt ≈A$0.6m).
  • Guidance credibility: FY26 revenue guidance cut from A$120–125m to A$105–115m within three months of reaffirmation; gross margin missed the >40% target.
  • Australian erosion: Home market revenue down 8% and 7% in FY25–FY26.
  • Customer concentration: Two customers accounted for A$29.8m (~29%) of FY25 revenue.
  • Leadership churn: Four CEOs (including interim) and three CFOs (including interim) between May 2023 and Aug 2026; Chair change in Sep 2025.
  • Legacy losses: Accumulated losses of A$326.0m (FY25); A$90m of goodwill impaired historically.

Opportunities

  • US private label/contract manufacturing: FDA variant application lodged 9 Sep 2026.
  • US premium natural tailwind: Segment growing ~44% versus ~3% for the total US category.
  • US white space: Expansion into Northeast, club, drug and specialty channels; e-commerce website relaunch.
  • China general trade and lower-tier cities: O2O at 1,800+ stores (+39%) with sell-out +30%; KidsWant entry; China-label CapriLac.
  • New markets: Canada entered; Mexico (A$1.1bn market) and Vietnam relaunch targeted.
  • Adjacencies: Supplements, RTD, sachets, toddler and adult nutrition, extending lifetime value.

Threats

  • Tariffs and trade policy: Total tariff costs rose to A$2.6m in FY26, concentrated in H2 (A$2.3m).
  • Regulatory resets in Asia: Vietnam and Singapore trading paused in H2 FY26; China customs/testing changes.
  • Geopolitics/logistics: Middle East / US–Iran conflict cited as a cost driver (Q3 FY26; Strategy Update).
  • Demographics: China births down 17% (CY25); shrinking Australian 0–36-month cohort.
  • Competitive intensity: Multinationals and challengers (Kendamil, Kabrita, ByHeart, Bobbie) targeting premium/goat niches.
  • Food safety/recall risk: Category-wide recalls (cited in FY26 Presentation) can rapidly shift consumer trust and retailer behaviour.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Apr 2025ACICA arbitration awards: A$22.9m vs Alice Trading, A$2.6m vs Willis Trading (former China customers)Non-cash A$3.6m benefit recognised; further recovery uncertain
Jun 2025NIFS lodged with FDA for three formulasFormal step toward permanent US access
Jun 2025Chair Katrina Rathie named Small Company Chair of the Year (AFR Boss Director Awards)Governance turnaround recognition
28 Jul 2025Q4 FY25 update: FY25 revenue A$102.5m (+29%); positive OCFTurnaround confirmed
28 Jul 2025Joe Coote appointed CEO; Reg Weine exitsSecond CEO change in ~2 years
29 Aug 2025FY25 results: maiden NPAT A$5.5m; NAB A$10m facility extended to Aug 2026; going-concern material uncertainty tied to FDAProfitability milestone with regulatory caveat
Sep 2025Rathie resigns; Paul Jensen becomes Chair; Coote joins board as MDBoard reshaped
Sep 2025Jensen buys 630,890 sharesInsider buying
20 Nov 2025AGM: FY26 revenue guidance A$120–125mAmbitious growth target set
31 Dec 2025Original FDA temporary discretion period end date (per FY25 AR); imports continued pending reviewRegulatory overhang
30 Jan 2026Q2 FY26: 1H revenue A$55.5m (+14%); cash A$9.9mMomentum, inventory build
27 Feb 20261H FY26 results: underlying EBITDA A$4.4m, reported EBITDA A$3.0m; FY26 EBITDA guidance upgraded to A$4–6m; Australian food portfolio exitedPeak of guidance confidence
Mar 2026Jensen buys 1.0m sharesInsider buying
26 Mar 2026Strategy Update Day: 2030 strategy; ELT introduced; US share 1.3%, Australia share 5.1%Strategic framework
30 Apr 2026Q3 FY26: revenue A$25.5m (+10%); US store distribution +~98%; liquidity A$21.9m; geopolitical logistics costs (Middle East)Early warning on costs
21 May 2026Lori Tauber Marcus appointed Independent NEDUS consumer expertise on board
29 May 2026FY26 trading update downgrade: revenue A$105–115m; reported EBITDA −A$2m to +A$2mGuidance miss; regulatory reset, freight, tariffs
Jul 2026US ranging exceeds 10,000 storesDistribution milestone
Late Jun 2026Entry into KidsWant (China)China offline expansion
H2 FY26Trading paused in Vietnam and Singapore pending new regulatory requirementsMaterialised regulatory risk
31 Jul 2026Q4 FY26: Q4 revenue +11%; cash A$9.4m; inventory A$35.7mLiquidity tightened
4 Aug 2026Notice of FY26 results; CFO Chris Rowe namedFinance leadership change
27 Aug 2026FY26 results: revenue A$111.9m; reported EBITDA −A$1.8m; NPAT −A$4.6m; NAB facility to Aug 2027Mixed result
31 Aug–1 Sep 2026Chair buys 1.5m shares (~A$130,500)Insider buying days before FDA news
4 Sep 2026FDA email received ~8:55am AEST; trading pause then haltDisclosure process
7 Sep 2026Permanent FDA authorisation announced; shares close +30–35% (intraday high A$0.145)Transformational regulatory milestone
8 Sep 2026Bell Potter lifts price target from 13.5c to 19cSell-side re-rating
9 Sep 2026FDA variant application lodged for contract manufacturingPrivate label optionality
10 Sep 2026Investor webinar; response to ASX aware letter defending disclosure timingContinuous disclosure scrutiny

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 89.3 Mn in FY2022 to AUD 111.9 Mn in FY2026.
Bubs Australia Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue89.360.179.7102.5111.9
Gross profit28.9-9.438.749.144.5
Underlying gross profit———49.752.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Bubs FY26 Results Release (27 Aug 2026) (bulletin.webull.com)
  2. Bubs FY26 Results Presentation (27 Aug 2026) (bulletin.webull.com)
  3. Q4 FY26 Quarterly Activities Report / Appendix 4C (31 Jul 2026) (investor.bubsaustralia.com)
  4. Notice of FY26 Results (4 Aug 2026) (investor.bubsaustralia.com)
  5. FY26 Trading Update (29 May 2026) (investor.bubsaustralia.com)
  6. Appointment of Independent NED (21 May 2026) (investor.bubsaustralia.com)
  7. Strategy Update Presentation (26 Mar 2026) (investor.bubsaustralia.com)
  8. Strategy Update Day notice (12 Mar 2026) (investor.bubsaustralia.com)
  9. 1H FY26 Results Presentation (27 Feb 2026) (investor.bubsaustralia.com)
  10. InvestSMART announcement summaries (1H FY26, Q2/Q3 FY26, trading update, AGM) (investsmart.com.au)
  11. FY25 Annual Report (investor.bubsaustralia.com)
  12. FY25 results release and Appendix 4E (29 Aug 2025) · announcements.asx.com.au
  13. Q4 FY25 Appendix 4C (28 Jul 2025) (investor.bubsaustralia.com)
  14. CEO appointment announcement (28 Jul 2025) (announcements.asx.com.au)
  15. 1H FY25 results · investor.bubsaustralia.com
  16. FY24 Appendix 4E and results · investor.bubsaustralia.com
  17. 1H FY24 commentary (investor.bubsaustralia.com)
  18. Q2 FY24 4C (investor.bubsaustralia.com)
  19. Governance changes (Nov 2023) (investor.bubsaustralia.com)
  20. FY23 results (investor.bubsaustralia.com)
  21. FY22 annual results · Q4 FY22 4C
  22. FY19 preliminary results (announcements.asx.com.au)
  23. FDA authorisation announcement (7 Sep 2026) (announcements.asx.com.au)
  24. Quartr FDA webinar summary (quartr.com)
  25. FilingReader (ASX aware letter) (filingreader.com)
  26. Reuters via KFGO (share reaction) (kfgo.com)
  27. Motley Fool Australia (Bell Potter target; insider buying; halt) · webull.com · fool.com.au
  28. Business News Today (FDA, price) (business-news-today.com)
  29. Just Food (FDA approval; CEO change; legal settlement; Deloraine) · just-food.com · just-food.com · just-food.com
  30. Inside FMCG (Carr termination; new chair) · insidefmcg.com.au
  31. Food & Drink Business (board changes, FY23, FY24, FDA) · foodanddrinkbusiness.com.au · foodanddrinkbusiness.com.au
  32. Business News Australia (Deloraine; FY22; capital raise; chair change) · businessnewsaustralia.com · direct.businessnewsaustralia.com · businessnewsaustralia.com
  33. NutraIngredients (FY24 regional detail) (nutraingredients.com)
  34. Stockwirex (FY26 and 1H FY26 coverage) · stockwirex.com
  35. FNArena (broker commentary) (fnarena.com)
  36. StockAnalysis (income statement history) (stockanalysis.com)
  37. Simply Wall St (ownership, listings) (simplywall.st)
  38. IBISWorld (incorporation date, employees) (ibisworld.com)
  39. Stocks Down Under (listing history) (stocksdownunder.com)
  40. a2 Milk Company FY26 results (17 Aug 2026) · announcements.nzx.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.